FDA Approves Degevma, a Denosumab Biosimilar, for Multiple Indications

The FDA has approved denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva), covering all original indications. This includes preventing skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors, treating giant cell tumor of bone in adults and adolescents, and managing hypercalcemia of malignancy. This approval offers an additional treatment option, potentially increasing access and affordability for patients.